Consumer bodies urge EMA to "go further" on trial data disclosure
This article was originally published in Scrip
Consumer and activist groups have welcomed the European Medicines Agency's draft policy on proactive disclosure of clinical trial data, but have urged it to go further and apply the policy to trials of drugs already on the market, rather than just those submitted for approval from January next year.
You may also be interested in...
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.